ENTERO HEALTHCARE STOCK OUTLOOK
ETMarkets Smart Talk: India's economy poised for strong growth in second half of 2024, market outlook cautious: Vipul Bhowar
India's economy is expected to experience strong growth in the second half of 2024. This growth will be fuelled by robust public investment and resilient private consumption, supported by strong domestic factors, decreasing inflation, and favourable fiscal and monetary policies.
Ahead of Market: 10 things that will decide D-Street action on Friday
While the Nifty's overall trend appears positive across different time frames, it is currently facing resistance around the 24,400 level, which coincides with a 1.618% Fibonacci Extension. This suggests the possibility of a temporary consolidation or minor dip in the upcoming trading sessions before the index potentially resumes its upward movement.
IT stocks: A comeback which just needs a bit more confirmation; 7 stocks with an upside potential of up to 23%
Just before the expiry of the June series contract, bulls were seen in a segment of the market which has been long ignored by them — IT stocks. Because the upward movement was taking place at the end of expiry, one could not rule out the element of short covering. If one looks a bit deeper in the trend in IT stocks, two things have become clear. That while the news and opinion has been negative, the price action has not been so bad as has been painted. Now let's look at what happened in the IT sector and why there could be a case for contrarian buying. Yes, the sector has some headwinds which not many had thought would appear two years back. But the bigger question is whether this phase of underperformance is about to get over or not. It might be time to shed the bias of negativity around large IT players.
Fresh capital raised via IPOs surges to a 9-year high, hints at private capex revival
Of the ₹33,610 crore raised by 37 companies so far in 2024, about 45%, or ₹15,190 crore, were through new shares, the highest proportion since 2015, when India Inc. raised nearly 48% fresh capital, according to data from primedatabase.com. The funds raised as fresh issues in 2024 were to either finance capital assets or retire existing debt obtained to build capacities, according to IPO documents.
73% IPOs trading above issue price as primary market shines in H1, four turn multibaggers
The fundraising of Rs 26,272 crore, however fell short of the previous two years likely due to the absence of mega issues. Investors' reception also remained positive with only one failed IPO.
These healthcare and pharma stocks may deliver more than 20% in one year
Check out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focusing on five key components - earnings, fundamentals, relative valuation, risk and price momentum to generate standardized scores. SR+ Reports is a complimentary offering to ETPrime members.
- Go To Page 1
Ahead of Market: 10 things that will decide D-Street action on Thursday
The Nifty index ended flat after a strong initial hour of trading, facing resistance around 23,400. Despite this, the short-term trend remains positive as the index stayed above 23,300. In the near term, the index is likely to continue consolidating within the 23,300-23,500 range. A decisive breakout above 23,500 could potentially trigger a rally towards 23,800.
Countdown for first 100 days of Modi 3.0 begins. What should stock investors do?
Countdown for the first 100 days of Modi 3.0 has stock market investors debating over the continuation of winners from Modi 2.0, with Sensex performance in focus.
Ahead of Market: 10 things that will decide D-Street action on Friday
The NSE Nifty 50 index ended 0.89% higher at 22,821 points and the S&P BSE Sensex rose 0.93% to 75,074, adding to their gains of more than 3% on Wednesday.
Valuations in PSU capital goods, infra & defence remain expensive: Pratik Gupta
The macro environment is extremely stable, whether it is the fiscal deficit, the current account deficit, inflation, forex reserves, so that is really one of the big attractions for both global as well as domestic investors.
10 years of Modi: 670 small & midcaps zoom up to 48,000%; will the counters repeat show?
Small and midcap stocks witnessed massive surge under the Narendra Modi government in the last 10 years, with over 670 BSE-listed stocks turning multibaggers.
Ahead of Market: 10 things that will decide stock action on Tuesday
Indian shares closed marginally higher in a special session conducted on Saturday for stock exchanges to test a failsafe system for equity trading.
Defensive stocks: FMCG is “passe”; 8 stocks from two sectors may be called “new defensives” with upside potential of up to 32%
1994 to 2024 is a difference of 30 years, but there is one thing which has remained constant, advice to move to defensive stocks when markets are volatile or there is an event risk. Four questions need to be asked; first, what is a defensive stock? Second, is a stock which was considered a defensive in 1994 when the Indian economy was just opening, still a defensive stock in 2024 ? Third, should there be a new definition of defensive stock in 2024 ? Last but not the least, what are the new defensive sectors or stocks?
Stock picks of the week: 4 stocks with consistent score improvement and upside potential of up to 39%
Last week’s movement of the market has brought back some memories of what happened in March 2024. Given the event risk in terms of election results, we might see higher volatility as some profit booking takes place. If one is not a trader and knows how to hedge, it would be better to be cautious before investing. If one is taking fresh exposure to equity, ensure that there is some level of quality as far as the business and fundamentals are concerned. These selected stocks depict a strong upward trajectory in their overall average score which is based on five key pillars i.e. earnings, fundamentals, relative valuation, risk and price momentum. This implies that there has been a significant improvement in their market outlook in the given time frame.
Better suited for volatile market: 5 largecaps from different sectors with upside potential of up to 47%
In the last few days bears are not making any distinction between large or mid or small cap stocks they just crush everything, it might appear that there is no point in making a distinction between these segments of the market. But the fact is that periods like this are a reminder of many basic things which one should remember before taking any investment decision in equity. First and foremost, after buying a stock you will own a business and what business you own is more important than what is happening to nifty or any other indices. Second, if you are a real long term investor then short term corrections should not bother you as they have come in the past and they will come in future also. What one should look for is whether the underlying business is witnessing any change or not and whether that change is positive or negative for the business. Last but not the least, do your homework before investing and not after investing.
Will short-term headwinds impact long-term potential? 6 stocks from hospital sector with upside potential of up to 30%
After outperforming the market, stocks from the healthcare sector or what is more commonly called hospital sector have gone into consolidation mode. The consolidation has been prompted by the fact that voices have been raised about differential pricing in the services of the hospitals. The matter has reached the Supreme Court and will be heard. Given the fact that while medicine is a science but in real life as practice it has an element of art in it. For example, a hospital who has a renowned surgeon from any branch, be it cardio, neuro on its roll may charge up more for the same surgery as compared to others. While the moral debate is on one side, there is another side to the story. In a country like India, the healthcare infrastructure needs vast expansion and upgradation. To some extent the street is ruthless and does not have much moral obligation.
Hot Stocks: Brokerages on RIL, Entero Healthcare, Natco Pharma and Persistent Systems
Brokerage Nomura upheld a neutral rating on Persistent Systems, while Investec continues to advocate a buy stance on Natco Pharma and has initiated a buy recommendation on Entero Healthcare. Conversely, CLSA has downgraded RIL to an outperform rating.
Nifty may test 25,800 in run-up to election results, says Prabhudas; picks 17 stocks to buy
PL has picked 7 largecap counters viz. HDFC Bank, ICICI Bank, Larsen & Toubro (L&T), Max Healthcare Institute, Maruti Suzuki, Reliance Industries (RIL) and Siemens. In the mid and smallcap universe, the top buys include the likes of Astral, Can Fin Homes, Eris Lifesciences, Grindwell Norton, Navneet Education, Praj Industries, RR Kabel, Safari Industries (India), Sunteck Realty and TCI Express.
Hot Stocks: Brokerages on Entero, CreditAccess, Bharti Hexacom, Interglobe and PVR
Brokerages initiate coverage and recommendations on Entero Healthcare, CreditAccess, Bharti Hexacom. Indigo Aviation downgraded by Axis Capital and Investec. CLSA retains buy on PVR Inox, emphasizing multiplexes as popular outdoor entertainment with growth plans in South India.
Shares worth $21 billion to enter market in 4 months as IPO lock-in period expires for 66 companies
66 companies are set to see the lock-in period for pre-listing shareholders lifted between March 4 and June 29. This amounts to $21.1 billion in value terms. The value pertains to the total lock-up opening shares, but not all the shares may be sold, as a sizable portion is also held by promoters and group entities
Entero Healthcare sees negative listing. Should investors exit?
Entero has incurred losses in the past three fiscal years, raising concerns about its financial sustainability and profitability. It also faces challenges with negative cash flows from all three major activities, impacting working capital requirements.
Entero Healthcare Solutions shares list at 2% discount to IPO price
Entero Healthcare's IPO debuted with a discount on BSE and NSE. Proceeds will be used for debt repayment, working capital, funding subsidiaries, and inorganic growth. The company has 73 warehouses and supply relationships with over 1,900 healthcare product manufacturers. The target addressable market is valued at Rs 2.7 lakh crore.
Stocks in news: Entero Healthcare, YES Bank, Alpex Solar, Max Financial, UPL
Global private equity major Carlyle Group on Thursday sold 1.4% stake in private sector lender YES Bank for approximately Rs 1,057 crore.
Entero Healthcare shares to list on Friday. What GMP signals ahead of D-St debut
In the unlisted market, the company's shares are trading with a marginal premium of Rs 2, which indicates a flat or even a discounted debut at the bourses. The IPO comprised a fresh equity issue of Rs 1,000 crore and an offer for sale of up to 47.69 lakh shares.
Entero Healthcare Solutions IPO allotment: Check status, GMP, listing date and other details
To check the status of Entero Healthcare Solutions allotment through the registrar, which is Bigshare Services in this case, kindly follow the below steps.
Entero Healthcare IPO fully subscribed on final day. Check subscription, GMP and other details
Entero Healthcare IPO comprises a fresh equity issue of Rs 1,000 crore and an OFS of up to 47.69 lakh shares. Prabhat Agrawal, Prem Sethi, Orbimed Asia Iii Mauritius, Chethan MP, and Deepesh T Gala, among others, will offload shares under the OFS. The shares are trading with a marginal premium of Rs 10 in the grey market.
Entero Healthcare IPO sees tepid response. Check subscription, GMP, and other details
Entero Healthcare IPO price band has been fixed from Rs 1,195-1258 per equity share. Bids can be made for a minimum of 11 shares and in multiples thereafter. the shares are trading with a marginal premium of Rs 5 in the grey market.
Entero Healthcare is going to expand more into tier II, tier III cities now
"In the last three years, our average annual growth rate has been 36% and once the IPO proceeds and we receive that money, we will be even more aggressive in terms of pursuing growth opportunities. In terms of business mix, 95% is coming from distribution services, but we also provide a lot of value-added services to these companies in terms of providing marketing and promotion services as well but that contributes less than 5% of our business as of now."
ETIG IPO Analysis: Entero Healthcare may Offer Better Value Post Listing
Incorporated in 2018 and founded by a former chief executive of Alkem Laboratories, Mumbai-based Entero Healthcare Solutions has grown to be among India's top three pharma distribution companies.
Load More
